Our Most Recent Episodes
Dr. Saad Usmani, MD Levine Cancer Institute Interview Date: June 27, 2014 Summary Dr. Saad Usmani is the new director of the Plasma Cell Disorder program and the director of Clinical Research in Hematology myeloma program at the Levine Cancer Institute. He shares three key lessons he learned through his work at UAMS: all myeloma is […]
New, Comprehensive Site for the Myeloma Community
A myeloma diagnosis is overwhelming and the learning curve is steep.
The myelomacrowd.org website was created by patients for patients and offers a comprehensive and current view of Myeloma— all in one place.
Together as patients and caregivers we can make more informed decisions about our care that will drive better outcomes for us all. Register and join the Myeloma Crowd today!
Our Next Episode
Our Next Show: The new Hevylite® test for myeloma patients – a deeper and more informative myeloma diagnostic
Friday, July 18, 2014, 8 am PDT, 9 am MDT, 10 am CDT, 11 am EDT
Call In by Phone to Listen Live: (347) 637-2631 or
Most myeloma patients know that they have either “kappa” or “lambda” myeloma. The commonly used FreeLite® test tells patients their kappa and lambda levels and the ratio between the two, which is an important indicator of the presence and aggressiveness of the disease. But what about the heavy part of the chain? A new test called Hevylite® is now being used in the clinic to test the IgG, or heavy part of the chain for both kappa and lambda patients. Learn from Dr. Stephen Harding of The Binding Site Group in the UK about what the test tells us, why it is important, when and how patients can access it in the clinic. This show was requested by patients who want to better understand newer myeloma tests that can lead to more personalized care.
Dr. Stephen Harding is the Research Director of The Binding Site Group, Ltd. Dr. Harding has spent the majority of his professional career developing antibodies (both monoclonal and polyclonal). These antibodies have been used in immunotherapies and latterly in immunodisgnostics. Dr. Harding is passionate about proteins and assay development and has been instrumental in the launch of Hevylite® a novel IVD assay for the quantification of Ig’kappa and Ig’lambda serum immunoglobulins. In addition, Dr. Harding has been instrumental in the launch of approximately 20 other IVD assays. Currently, he runs a team of 60 R&D scientists and a regulatory affairs department with a keen interest in 510k FDA submissions. Dr. Harding has contributed to many articles in peer reviewed journals and tens of published abstracts.
Our Previous Episodes
What's new in MGUS? Very interesting ASCO findings and the diagnostics you need to have as an MGUS patient with Dr. Brendan Weiss, MD
The hopeful discovery of an engineered measles virus for myeloma treatment with Dr. Stephen Russell, MD, PhD
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
A compelling European approach in myeloma care: Collaboration, Referrals and Established Guidelines with Dr. Pieter Sonneveld, MD, PhD, Erasmus MC
Myeloma is not a single disease: The illuminating discovery and implications for care with Dr. Michael Kuehl, MD, PhD of the NCI
Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants
Three myeloma themes with Dr. Robert Z. Orlowski of MD Anderson Cancer Center:Immunotherapy, making transplant better and using new small molecules for more convenient myeloma care
Dr. Leif Bergsagel, MD of the Mayo Clinic shares the impact of the MYC translocation in myeloma progression and relapse and a new target that boosts immunity while impacting myeloma cells
Genes that drive myeloma growth and why new discoveries of myeloma's complexities are hopeful with Dr. Jens Lohr, MD of The Broad Institute and Dana Farber Cancer Institute
Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission
Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the "Valley of Death"
Our Next Show: How does a drug begin as an idea and become an actual myeloma therapy in the clinic? Dr. Craig Crews, Crews Laboratory at Yale University discusses his discovery and development of carfilzomib (Kyprolis)
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases
Dr. Philip McCarthy of Roswell Park Cancer Institute on transplants: best induction therapies, best approaches for high risk and how patients can recover faster
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation) to selectively target only active myeloma cells using the common CD38 protein
Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
Shutting down myeloma growth by changing the soil where it grows with Dr. Noopur Raje of Massachusetts General Hospital Cancer Center
What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.
Are you confused by your myeloma labs? Dr. Michael Misialek says your pathologist is ready and willing to help decipher the results.
The path to personalized medicine: Dr. Gareth Morgan describes his work to subdivide myeloma into actionable types, target specific genes and pathways, and study the impact of the bone marrow environment
Dr. Rodger Tiedemann discusses why myeloma persistently returns and his work to strike at the root of the disease by targeting earlier stage progenitor cells
Find a multiple myeloma specialist near you. We’ve moved this directory to the www.myelomacrowd.org site.